Publication | Open Access

Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group

Phase Ii TrialMedicineImmunologyPathologyRecurrent Osteosarcoma Aost1521Immune Checkpoint InhibitorTumor TargetingGlembatumumab VedotinCancer TreatmentOncologyRadiation Oncology